Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Outcomes and Prognostic Factors in Pediatric Oligodendroglioma: A Population-Based Study

Goel N.J.a · Abdullah K.G.b · Lang S.-S.b, c

Author affiliations

aPerelman School of Medicine and bDepartment of Neurosurgery, University of Pennsylvania, and cDivision of Neurosurgery, The Children's Hospital of Philadelphia, Philadelphia, PA, USA

Related Articles for ""

Pediatr Neurosurg 2018;53:24-35

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: May 22, 2017
Accepted: September 12, 2017
Published online: November 02, 2017
Issue release date: December 2017

Number of Print Pages: 12
Number of Figures: 4
Number of Tables: 2

ISSN: 1016-2291 (Print)
eISSN: 1423-0305 (Online)

For additional information: https://www.karger.com/PNE

Abstract

Background/Aims: Pediatric oligodendroglioma (pODG) is a rare primary brain tumor that remains poorly understood. Demographics, outcomes, and prognostic factors were analyzed in 346 pODG cases from the Surveillance, Epidemiology, and End Results database. Methods: Gender, race, age, tumor location, tumor size, tumor grade, extent of resection, and use of radiotherapy were evaluated with respect to overall survival (OS) by univariate and multivariate analysis. These factors were assessed in the pediatric cohort and 5,753 adult oligodendroglioma cases for comparison. Results: The mean OS in pODG was 199.6 months. Five- and 10-year survival rates were 85 and 81%. pODG arose less frequently in the frontal lobe than adult tumors (53 vs. 22%) but was more common in the temporal lobe (32 vs. 18%) and extracortical regions (19 vs. 5%, p < 0.0001). pODG presented with smaller size (55 vs. 24%, p < 0.0001) and lower grade (72 vs. 54%, p < 0.0001) than adult tumors. Tumor location, size, grade, use of radiotherapy, and extent of resection were significant prognostic factors. Size and grade were much stronger prognostic factors in children than adults. While children with oligodendroglioma survive much longer than adults on the whole, there was no difference in outcome between children with high-grade tumors and adults with high-grade tumors. Conclusion: pODG differs significantly from adult oligodendroglioma along a number of demographic and tumor factors at a population level, and key prognostic factors influence survival differently in pODG than in adult disease.

© 2017 S. Karger AG, Basel


References

  1. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J: CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol 2014;16:1-63.
  2. Qaddoumi I, Sultan I, Gajjar A: Outcome and prognostic features in pediatric gliomas: a review of 6,212 cases from the Surveillance, Epidemiology, and End Results (SEER) database. Cancer 2009;115:5761-5770.
  3. Davis FG, Freels S, Grutch J, Barlas S, Brem S: Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 1998;88:1-10.
  4. Van den Bent MJ, Bromberg JE, Buckner J: Low-grade and anaplastic oligodendroglioma. Handb Clin Neurol 2016;134:361-380.
  5. Minniti G, Arcella A, Scaringi C, Lanzetta G, Di Stefano D, Scarpino S, Pace A, Giangaspero F, Osti MF, Enrici RM: Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers. J Neurooncol 2014;116:275-282.
  6. Wesseling P, van den Bent M, Perry A: Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathol 2015;129:809-827.
  7. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
  8. Smith JS, Alderete B, Minn Y, Borell JT, Perry A, Mohapatra G, Hosek S, Kimmel D, O'Fallon J, Yates A, Feuerstein BG, Burger PC, Scheithauer BW, Jenkins RB: Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999;18:4144-4152.
  9. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP: Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994;145:1175-1190.
  10. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD: IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-773.
  11. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendroglioma, astrocytomas, and mixed oligastrocytomas. J Clin Oncol 2000;18:636-645.
  12. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-1479.
  13. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW: The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131:803-820.
  14. Simonetti G, Gaviani P, Botturi A, Innocenti A, Lamperti E, Silvani A: Clinical management of grade III oligodendroglioma. Cancer Manag Res 2015;7:213-223.
  15. Shaw EG, Scheithauer BW, O'Fallon JR: Supratentorial gliomas: a comparative study by grade and histologic type. J Neurooncol 1997;31:273-278.
  16. Giannini C, Scheithauer BW, Weaver AL, Burger PC, Kros JM, Mork S, Graeber MB, Bauserman S, Buckner JC, Burton J, Riepe R, Tazelaar HD, Nascimento AG, Crotty T, Keeney GL, Pernicone P, Altermatt H: Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 2001;60:248-262.
  17. Kros JM, Gorlia T, Kouwenhoven MC, Zheng PP, Collins VP, Figarella-Branger D, Giangaspero F, Giannini C, Mokhtari K, Mørk SJ, Paetau A, Reifenberger G, van den Bent MJ: Panel review of anaplastic oligodendroglioma from European Organization for Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 2007;66:545-551.
  18. Van den Bent MJ: Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol 2010;120:297-304.
  19. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK: Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997;79:1381-1393.
  20. Nauen D, Haley L, Lin MT, Perry A, Giannini C, Burger PC, Rodriguez FJ: Molecular analysis of pediatric oligodendrogliomas highlights genetic differences with adult counterparts and other pediatric gliomas. Brain Pathol 2016;26:206-214.
  21. Rodriguez FJ, Tihan T, Lin D, McDonald W, Nigro J, Feuerstein B, Jackson S, Cohen K, Burger PC: Clinicopathologic features of pediatric oligodendrogliomas: a series of 50 patients. Am J Surg Pathol 2014;38:1058-1070.
  22. Creach KM, Rubin JB, Leonard JR, Limbrick DD, Smyth MD, Dacey R, Rich KM, Dowling JL, Grubb RL Jr, Linette GP, King AA, Michalski JM, Park TS, Perry A, Simpson JR, Mansur DB: Oligodendrogliomas in children. J Neurooncol 2012;106:377-382.
  23. Suri V, Jha P, Agarwal S, Pathak P, Sharma MC, Sharma V, Shukla S, Somasundaram K, Mahapatra AK, Kale SS, Sarkar C: Molecular profile of oligodendrogliomas in young patients. Neuro Oncol 2011;13:1099-1106.
  24. Kreiger PA, Okada Y, Simon S, Rorke LB, Louis DN, Golden JA: Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas. Acta Neuropathol 2005;109:387-392.
  25. Peters O, Gnekow AK, Rating D, Wolff JE: Impact of location on outcome in children with low-grade oligodendroglioma. Pediatr Blood Cancer 2004;43:250-256.
  26. Raghavan R, Balani J, Perry A, Margraf L, Vono MB, Cai DX, Wyatt RE, Rushing EJ, Bowers DC, Hynan LS, White CL: Pediatric oligodendrogliomas: a study of molecular alterations on 1p and 19q using fluorescence in situ hybridization. J Neuropathol Exp Neurol 2003;62:530-537.
  27. Myal Y, Del Bigio MR, Rhodes RH: Age-related differences in 1p and 19q deletions in oligodendrogliomas. BMC Clin Pathol 2003;3:6.
  28. Bowers DC, Mulne AF, Weprin B, Bruce DA, Shapiro K, Margraf LR: Prognostic factors in children and adolescents with low-grade oligodendrogliomas. Pediatr Neurosurg 2002;37:57-63.
  29. Razack N, Baumgartner J, Bruner J: Pediatric oligodendrogliomas. Pediatr Neurosurg 1998;28:121-129.
  30. Rizk T, Mottolèse C, Bouffet E, Jouvet A, Guyotat J, Bret P, Lapras C: Cerebral oligodendrogliomas in children: an analysis of 15 cases. Childs Nerv Syst 1996;12:527-529.
  31. Tice H, Barnes PD, Goumnerova L, Scott RM, Tarbell NJ: Pediatric and adolescent oligodendroglioma. AJNR Am J Neuroradiol 1993;14:1293-1300.
  32. Wang KC, Chi JG, Cho BK: Oligodendroglioma in childhood. J Korean Med Sci 1993;8:110-116.
  33. Favier J, Pizzolato GP, Berney J: Oligodendroglial tumors in childhood. Childs Nerv Syst 1985;1:33-38.
  34. Dohrmann GJ, Farewell JR, Flannery JT: Oligodendrogliomas in children. Surg Neurol 1978;10:21-25.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: May 22, 2017
Accepted: September 12, 2017
Published online: November 02, 2017
Issue release date: December 2017

Number of Print Pages: 12
Number of Figures: 4
Number of Tables: 2

ISSN: 1016-2291 (Print)
eISSN: 1423-0305 (Online)

For additional information: https://www.karger.com/PNE


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.